Twinbeech Capital LP Corcept Therapeutics Inc Transaction History

Twinbeech Capital LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$21.44 - $25.15 $673,044 - $789,508	31,392 New	31,392 $698,000
Q4 2022 Feb 14, 2023	BUY	$19.95 - $29.96 $404,526 - $607,498	20,277 New	20,277 $411,000
Q2 2021 Aug 16, 2021	SELL	$19.97 - $24.43 $244,632 - $299,267	-12,250 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$23.49 - $30.56 $278,098 - $361,799	-11,839 Reduced 49.15%	12,250 $291,000
Q4 2020 Feb 16, 2021	BUY	$16.78 - $27.3 $404,213 - $657,629	24,089 New	24,089 $630,000

403

84.3M

1.04M

1.33M

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $6.81B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

Stay updated on Twinbeech Capital LP with notifications on news.